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The etiological agent for the ongoing pandemic of COVID-19 is a novel 
coronavirus, known as Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS-CoV-2). The most common symptoms of COVID-19 include fever, 
dry cough, sore throat, and headache.1 Severe disease can progress to 
the highly morbid outcome of Acute Respiratory Distress Syndrome 
(ARDS).2 The number of infected individuals during this pandemic is 
high while the worldwide mortality rate remain slow.3 According to 
World Health Organization (WHO) guidelines, the infected patient should 
be discharged from hospital after containment period of 14 days along 
with two consecutive negative Quantitative Reverse Transcription 
Polymerase Chain Reaction (RT-qPCR) results of respiratory specimens 
at least 24 hours apart.4 During January 28 to March 13, COVID-19 relapse 
cases have been documented in Shangqui, Henan province and later in 
Korea.5,6 Pathogenesis of these relapse cases needs further exploration 
as they hold important links towards the development of a second 
wave of the pandemic. Here in this article, we propose the following 
hypotheses on how COVID-19 relapse can play a significant role in 
disease burden and further horizontal transmission based on available 
evidence. 
 
Relapse vs. Reinfection: Immunological Perspective 
The second wave of infection among COVID-19 patients has dazed the 
scientific world, but it has to be decided whether the second wave of 
infection is due to reinfection or relapse. According to recent 
documentation from China5 and Korea,6there have been recovered 
patients testing positive after one or two consecutive negative results. 
Various methods for the diagnosis of the infection are used. These 
include RT-qPCR, high-throughput sequencing, CT scan, and 
immunological detection kits.7 Furthermore, improper sampling 
procedure, different source of swab samples, and variable 
specificity/sensitivity of nucleic acid tests can lead to the false negative 
RT-qPCR results implying the persistence of infection rather than 
recurrence or relapse.7,8 This particular limitation of antibody testing 
method should be carefully considered before declaration of reinfection 
or relapse. The durability of the infected patient’s immune response 
plays a significant role to determine the reinfection. The presence of 
CD4+ T cells and memory CD8+ T cells are found to be protective in case 
of Coronavirus mediated infection by producing effector cytokines and 
IFN-gamma.9It is also noted that immunoglobulins alone are not 
sufficient to provide long-term immunity.10 Accumulating evidence have 
shown that virus specific CD8+ T cells were persistent up to 6 years 
after Severe Acute Respiratory Syndrome Coronavirus 1 (SARS-CoV-1) 
infection, but memory B cells and accompanying antibodies were 
undetectable at that time.11 A similar scenario may result from SARS-
CoV-2 infection as it shows phylogenetic similarity with SARS-CoV-1.12 A 
recent study performed by Zhang and colleagues investigated 
monocyte expression of Angiotensin Converting Enzyme 2 (ACE2), the 
endogenous entry receptor of SARS-CoV-2. They came to the conclusion 
that monocytes of COVID-19 patients express a lower concentration of 
ACE2 in comparison to healthy individuals.13 Therefore, it can be 
interpreted that SARS-CoV-2 might exist in human Peripheral Blood 
Mononuclear Cells (PBMCs) (monocytes mainly) and cause relapse after 
negative PCR on samples from the respiratory tract.14 Considering the 
aforementioned facts, further research work is required for fine 
delineation between relapse and reinfection. 
 
Probable Association of Phylogenetic Perspective with Relapse 
Distinct viral clades of SARS-CoV-2 (e.g., A2a, B1) appears to result in 
variation of virulence.15Considering this fact, there is a possibility that 
duration between primary infection and relapse may vary across 
different clades. Furthermore, there is a possibility that the nature and 
affinity of protective neutralizing antibodies (NAbs) may vary for 
different strains as well. Hence, it can be hypothesized that NAbs of 
primary infection may be unable to protect re-infection by other strains. 
It also remains to be seen whether, in the case of relapse, there is an 
insufficient increase in NAbs during the second course of infection. 
 
Viral Reactivation in SARS-CoV-2 Relapse 
Viral latency period might be considered as a potential factor in order 
to determine relapse or reactivation. Reports have suggested disparity 
amongst proposed viral latency period with a maximum duration of 24 
days.16 According to an article by Ye et al, the reported reactivation 
among 5 patients was a maximum time period of 17 days, but proper 
clinical characteristics to distinguish reactivation with relapse was not 
properly demarcated.17 It might be suggested that the virus causes 
latent infection of cells, while later on the genome gets transcribed and 
translated into viral proteins. Hence, it could be inferred that the virus 
gets reactivated from a latent stage to a lytic stage where manifestation 
of symptoms might be observed as similar phenomenon were already 
observed for many other viruses.18 Additionally, SARS-CoV-2 can survive 
and replicate in neuronal cell lines.19 Therefore, another indication 
towards viral latency through neuro-invasion of virus and reactivation 
at a later stage is suggested. Considering the abovementioned fact, an 
important question can be raised: Can an asymptomatic individual with 
a latent infection spread the virus without being detected? Proper 
clinical investigation into the potential reactivation of this virus requires 
immediate further study. 
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Consideration of Viral Shedding to Determine Relapse or Reinfection 
Another undermined and potentially influential factor might be the viral 
shedding which may cause transmission from an apparently recovered 
individual or asymptomatic individual to a healthy individual.20 The viral 
shedding may begin 2-3 days before the appearance of symptoms with 
viral loads decreasing monotonically after onset of symptoms.21 The 
virus has been detected in patients at a median of 20 days and up to 
37 days post-infection.22 The viral transmission not only comes through 
droplet or aerosol route but also through the fecal-oral route.23,24 The 
participation of tears and conjunctival secretions in viral shedding has 
also been speculated.25 All of these non-classical or non-respiratory 
tract routes of virus shedding might go unrecognized during discharge 
of patients who are tested negative through nasopharynageal swab RT-
qPCR alone. It is possible that viral titers are still relatively high in 
various non-classical transmission sites of recovered patients, 
indicating that they are not only able to spread the infection but also 
may relapse themselves. 
 
Conclusion 
In conclusion, the ongoing public health emergency should look after 
protocols regarding both molecular testing and antibody testing to 
contain the pandemic. The infected individuals should strictly be 
discharged only after two proper consecutive RT-PCR negative results 
of swab samples from various sources so that it can reduce clinically 
recovered individuals with apparently hidden viral source. Even after 
that, the convalescent patients should be monitored by the health 
system during the post-discharge domiciliary quarantine period of 14 
days, and on completion of this period they should be tested again. 
This should thereby avoid increment in numbers of asymptomatic 
individuals with reactivation or relapse. Moreover, antibody testing 
should not be authorized at the time of discharge as its variation of 
sensitivity/specificity has potential to provide unfounded confidence. 
That said, there remain a few unanswered questions at this point in 
time - Does the virus really clear out from the system after the primary 
infection?; Is it safe to assume that the  fragments of virus residing 
inside the body cannot infect someone after the first course of infection 
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